University Home | Hospital | Pulse Employment | Contact Us | Search | News 
Thomas Jefferson University Search Jefferson
Jefferson Medical College Jefferson College of Graduate Studies Jefferson College of Health Professions
Menu

Thomas Jefferson University - Hie-Won Yvonne Hann
Hie-Won Yvonne Hann

Medicine
Thomas Jefferson University
Jefferson Medical College
Department of Medicine
Division of Gastroenterology and Hepatology
Professor
Director, Liver Disease Prevention Center
Thomas Jefferson University Hospital
Appointed 1988
Mailing Address
1025 Walnut Street, Room 906
Philadelphia, Pennsylvania 19107
United States
Contact Information
Phone: 215-955-5806
Fax: 215-955-0770
Hie-Won.Hann@jefferson.edu
Expertise and Research Interests
Expertise: hepatitis B, hepatocellular carcinoma, preneoplastic markers, iron and cancer

Research Interests:

preneoplastic markers of HBV associated hepatocellular carcinoma. A longitudinal study of patients at pre-, during and post- hepatocellular carcinoma stages. (Co-Investigator of NIH funded research with Mark Feitelson,Ph.D.as the Principal Investigator)

P.I. at Thomas Jefferson University (Subcontracter) of the NIH grant
Identification of altered glycan and glycoproteins in viral induced liver cancer
(P.I. Anand Mehta, Ph.D. at Drexel University)

Clinical Research Interests have involved lamivudine, adefovir, entecavir, clevudine and telbivudine, tenofovir trials for the treatment of chronic hepatitis B in 25 clinical studies in the past and at present time.

Awards(total 18)
1993 "Women in Leadership Award" WOMENS WAY, Philadelphia

1995 "Fellow Koreans who did the Nation Proud Award" on the 50th Anniversary of Korean Liberation. Among the Korean American Physicians in the U.S.A., 11 were invited

1996 "Order of Civic Merit Award Mokryon-Jang" one of the highest honor given to civilians from The Korean Government(President Kim Young Sam) (for the 15 years'' campaign against Hepatitis B among Korean American Communities and for starting Free Counseling Center for Philadelphia Korean Community 10 years ago)

1999 "Distinguished Leadership Award" Hepatitis B Foundation, Philadelphia, PA

2000 "2000 Dream of Equality Award" Asian Americans For Equality New York, NY

2001 "Proud Alumnus Award" Seoul National University College of Medicine Seoul National University College of Medicine Alumni Association Seoul, Korea

2001 " Ham Choon Medical Science Award" Ham Choon Medical Science Award Committee Seoul National University College of Medicine and Seoul National University College of Medicine Alumni Association. Seoul, Korea

2003 "Distinguished Daughter of Pennsylvania" Governor of Pennsylvania, Commonwealth of Pennsylvania

2005 "Proud Ewha Alumnus Award #5" Ewha Girls'' High School and Alumni Association, Seoul, Korea

Keywords
hepatitis B, hepatocellular carcinoma, tumor enhancing effect of iron, iron and cancer
Publications
  • Selected papers (of 126 publications)

  • Hann, HWL., Levy, H.M. and Evans, A.E. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res 40:1411-1413, 1980.

  • Hann, HWL., London, W.T., Evans A.E. and Hann, R.S. Leukocyte migration inhibition by leukemia-associated antigen in children with acute leukemia and their family members. Cancer 46:293-298, 1980.

  • Hann, H.L., Lustbader, E.D., Evans, A.E., Toledano, S.R., Lillie, P.D. and Jasko, L.B. Lack of influence of T-cell marker and importance of mediastinal mass on the prognosis of acute lymphocytic leukemias of childhood. J. Natl. Cancer Inst. 66:285-290, 1981.

  • Hann, HWL., Evans, A.E., Cohen, I.J. and Leitmeyer, J.E. Biologic differences between neuroblastoma stages V-S and IV. Measurement of serum ferritin and E-rosette inhibition in 30 children. N. Engl. J. Med. 305:425-429, 1981.

  • Hann, HWL., Kim, C.Y., London, W.T., Whitford, P. and Blumberg, B.S. Hepatitis B virus and primary hepatocellular carcinoma: Family studies in Korea. Int. J. Cancer 30:47-51, 1982.

  • Hann, HWL., Nowell, P.C., Koch, P., Minowada, J., Leitmeyer, J.D. and August, C.S. Changes in clonal expression during the course of acute leukemia: Possible subsets in childhood leukemia. J. Natl. Cancer. Inst. 69:393-399, 1982.

  • Park, H.C., Kang, C.M., Kim, K.H., London, W.T., Hann, HWL. and Blumberg, B.S. Study on hepatitis B associated glomerular disease. Journal of Hanyang Medical College 2:81-87, 1982.

  • Lustbader, E.D., Hann, HWL. and Blumberg, B.S. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 220:423-425, 1983.

  • Hann, HWL. Hepatitis B and Primary Liver Cancer. Sigetop, Seoul National University College of Medicine Alumni Quarterly, June 25, 1983, pp. 6 and 10.

  • Hann, HWL., Stahlhut, M.W., and Chung, L.C. Inhibitory effects of isoferritins from tumor and non-tumor tissues on E-rosette formation. Letter to the Editor. Lancet 1:43, 1984.

  • Blumberg, B.S, Hann, HWL, Mildvan, D., Mathur, U., Lustbader, E. and London, W.T. Iron and iron binding proteins in persistent generalized lymphadenopathy and AIDS. Letter to the Editor. Lancet 1:347, 1984.

  • Hann, HWL., Stahlhut, M.W. and Millman, I. Human ferritins present in the sera of nude mice transplanted with human neuroblastoma or hepatocellular carcinoma. Cancer Res. 44:3898-3901, 1984.

  • Hann, HWL., Evans, A.E., Siegel, S.E., Wong, K.Y., Sather, H., Dalton, A., Hammond, D. and Seeger, R.C. Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: The Children's Cancer Study Group experience. Cancer Res. 45:2843-2848, 1985.

  • Kim, C-Y., Bae, S-K., Hann, H.L., London, W.T. and Blumberg, B.S. Prevalence of HBeAg and anti-HBe in chronic active hepatitis, cirrhosis and primary hepatocellular carcinoma in Korea. Hepatology 5:54-56, 1985.

  • Hann, H.L., Stahlhut, M.W. and Evans, A.E. The source of increased ferritin in neuroblastoma: Studies with Concanavalin A-Sepharose binding. J. Natl. Cancer Inst. 76:1031-1033, 1986.

  • Stevens, R.G., Morris, J.S., Hann, H.L., Pulsipher, B. and Stahlhut, M.W. Serum selenium assay following serum ferritin assay. Am. J. Epid. 124:329-331, 1986.

  • Hann, H.L. Biology of ferritin in Cancer. The Korea Medical News, No. 1592, pp. 12-13, 1986.

  • Evans, A.E., D'Angio, G.J., Propert, K., Anderson, J. and Hann, H.L. Prognostic factors in neuroblastoma. Cancer 59:1853-1859, 1987.

  • Hann, H.L. Prevention of hepatitis B and primary liver cancer in Asians, particularly Koreans, in the United States. In Proceedings 1986 Scientific Meeting, A New Approach Towards Safe Prevention of Hepatitis B Vaccine. Yuhan SmithKline Co. Ltd., Seoul, Korea, pp. 1-12, 1986.

  • Zhou, X.D., Stahlhut, M.W., Hann, H.L. and London, W.T. Serum ferritin in hepatocellular carcinoma. Hepatogastroenterology 35:1-4, 1988.

  • Hann, H.L. Prevention of Primary Hepatocellular Carcinoma. Bulletin, Korean Medical Association of America, 13(2), November 28, 1988, pp. 9-10.

  • Hann, H.L., Stahlhut, M.W. and Blumberg, B.S. Iron nutrition and tumor growth: decreased tumor growth in iron deficient mice. Cancer Res. 48:4168-4170, 1988.

  • Hann, H.L., Stahlhut, M.W. and Evans, A.E. Basic and acidic isoferritins in the sera of patients with neuroblastoma. Cancer 62:1179-1182, 1988.

  • Hann, H.L., Kim, C.Y., London, W.T. and Blumberg, B.S. Increased serum ferritin in chronic liver disease: A risk factor for primary hepatocellular carcinoma. Int. J. Cancer 43:376-379, 1989.

  • Hann, H.L., Stahlhut, M.W., Lee, S., London, W.T. and Hann, R.S. Effects of isoferritins on human granulocytes. Cancer 63:2492-2496, 1989.

  • Hann, H.L., Stahlhut M.W. and Hann, C.L. Effect of iron and deferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 11:566-569, 1990.

  • Hann, H.L., Lange, B.J., Stahlhut, M.W. and McGlynn, K.A. Prognostic importance of serum transferrrin and ferritin in childhood Hodgkin's disease. Cancer 66: 313-316, 1990.

  • Siegelman, E. S., Mitchell, D. G., Rubin, R., Hann, H.L., Kaplan, K. Steiner, R,M., Rao, V.M,, Burk, D.L. and Rifkin, M.D. Parenchymal versus reticuloendothelial iron overload in the liver: Distinction with MR imaging. Radiology 179: 361-366, 1991.

  • Mitchell, D.G., Palazzo, J, Hann, H.L, Rifkin M.D., Burk, D.L., Rubin R. Hepatocellular tumors with high signal on T1-Weighted MR Images: Chemical Shift MR Imaging and histologic correlation. J. Comp. Assist. Tomography. 15: 762-769, 1991.

  • Hann H.L. Viral Hepatitis Update: Prevention and Treatment. Korean Medical Association of America Quarterly 16: no. 2 , 13-15, 1991.

  • Simon, D., London, W.T., Hann, H.L, and Knowles, B.B. Chromosome abnormalities in peripheral blood lymphocytes of chronic carriers of HBV. Cancer Res. 15:6176-6179, 1991.

  • Hann, H.L., Stahlhut, M.W. and Menduke, H. Iron enhances tumor growth: observation on spontaneous mammary tumors in mice. Cancer 68: 2407-2410, l991.

  • Moody, D.E., Loury D.N., Hammock, B.D., Ruebner B.H., Cullen, J.M., Hillman, J.H., Hillman, D.W., Roa, M.S., London, W.T., Hann, H.L., Millam, I., Griffin M.J. Serum epoxide hydrolase (Preneoplastic Antigen) in human and experimental liver injury Cancer Epidemiology Biomarkers and Prevention. 1:395-403, 1992.

  • Mitchell DG, Palazzo J, Hann HL, Park CH, Tempany C, Chako A, Rubin R. Mass-like hepatic hypertrophy: MRI findings with histologic correlation. Magnetic Resonance Imaging 10: 541-547, 1992.

  • Hann, H.L., Stahlhut, M.W. Rubin, R. and Maddrey, W.C. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 70: 2051-2056, 1992.

  • Woods, W.G., Tuchman, M, Bernstein, M, Leclerc, J.M., Brisson, L, Look, T, Brodeur, G, Shimada, H, Hann, H.L., Robinson, L.L., Shuster, J, Lemieux, B. Screening for Neuroblastoma in North America: Two year results from the Quebec project . Am J Ped Hem/Oncol 414: 312-319. 1992

  • Mitchell DG, Palazzo J, Hann HL, Tempany C, Chako A, Rubin R. Mass-like hepatic hypertrophy: MRI findings with histologic correlation. Mag Res Imag 10: 541-547, 1992.

  • Palazzo JP, Lundquist K, Mitchell D, Mittal KR, Hann HL, Munoz S, Moritz MJ, Jacobs JM and Martin P. Rapid Development of Lymphoma following Liver Transplantation in a Recipient with Hepatitis B and Primary Hemochromatosis. Am J Gastroenterology 88 (1) 102-104, 1993.

  • Mitchell DG, Lovett KE, Hann HL, Ehrlich S, Palazzo J, Rubin R. Cirrhosis: multi-observer analysis of hepatic MRI findings in a heterogeneous population. JMRI 3: 313-321, 1993.

  • Kim IY, Mitchell DG, Vinitski S, Consigny PM, Hann HL, Rifkin MD, Rubin R. Magnetic resonance imaging of hepatic iron overload in rat. JMRI 3: 67-70, 1993.

  • Jacobs JM, Martin P, Munoz SJ, Westerberg S. Hann HW, Moritz MJ, Rubin R, Yang S, Rodamski J, Jarrell BE. Liver transplantation for chronic hepatitis B in Asian males. Transplantation porceedings 25: 1904-1906, 1993.

  • Sadek AG, Mitchell DG, Siegelman ES, Outwater EK, Matteucci T, Hann HW. Ealrly hepatocellular carcinoma that develops within macroregenerative nodules; growth rate depicted at serial MR imaging. Radiology 195: 753-756, 1995

  • Hann H.L. Primary hepatocellular carcinoma in relation to Hepatitis B and C viruses. J of Med Sci (The Korean-American Medical Association) 1: 47-54, 1995

  • Ito, K, Mitchell D, Hann HL, Outwater, E. Kim Y. Compensated cirrhosis due to viral hepatitis: MR imaging prediction of clinical progression. AJR 169: 801-805, 1997

  • Martin P, Hann HL, Westerberg S, Munoz S, Rubin R, Maddrey WC. Prospective controlled trial of interferon-alpha for chronic hepatitis B in Asian-Americans. Dig Dis Sci 43:875-879, 1998.

  • Ito K, Mitchell DG, Hann HWL, Outwater EK, Kim Y, Fujita T, Ozaki H, Honjo K, Matsunaga N. Progressive viral-induced cirrhosis: Serial MR imaging findings and clinical correlation. Radiology 207: 729-735, 1998

  • Hann H.L. Hepatocellular Carcinoma in Asian Americans. Cancer (Cancer supplement); 83: 1723-1729, 1998

  • Hann H.L. Liver Cancer Prevention and Control for Asian Americans. Asian American and Pacific Islander Journal of Health 6: 292-303, 1998

  • Ito, K, Mitchell DG, Gabata T, Hann HWL,Kim Pyo N, Fujita T, Awaya H, Honjo K, Matsunaga N. Hepatocellular carcinoma: Association with increased iron deposition in the cirrhotic liver at MR imaging. Radiology 212: 235-240, 1999

  • Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, Crowthers L, Condreay LD, Woessner BS, Rubin M, Brown NA for the U.S. Lamivudine Investigator Group. Lamivudine as Initial Treatment for Chronic Hepatitis B in Patients from the United States. New Engl J Med 341:1256-1263, 1999

  • Kunkle EJS, Kim JS, Hann HWL, Oyesanni O., Menefee LA, Field HL, Myers RE. Depression in Korean immigrants with hepatitis B and related liver diseases. Psychosomatics 2000;41:472-480

  • Brodeur GM, Look AT, Shimada H, Hamilton VM, Maris JM, Hann HW, Leclerc JM, Bernstein M, Brisson LC, Brossard J, Lemieux B, Tuchman M, Woods WG Biological aspects of neuroblastomas identified by mass screening in Quebec. Med Pediatr Oncolo 2001; 36: 157-9.

  • Kim M-J, Mitchell DG, Ito K. Hann HWL, Park YN, Kim PN. Hepatic iron deposition on MR imaging in patients with chronic liver disease: correlation with serial serum ferritin concentration. Abdominal Imaging 2001;26:149-156.

  • Jeong YY, Mitchelll DG, Hann HWL, Malin AK, Kang HK, Holland GA and Capizzi RL. Hepatocellular carcinoma after chemotherapy: Gadolinium-enhanced MR imaging measurement of necrosis by volume histogram. J Computed Assist Tomography 2001; 25:624-628.

  • Fontanta RJ, Hann HWL, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anseuetz G, Riker-Hopkins M, Brown N. A multicenter Study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001;7:504-510

  • Hann HWL. Update of hepatitis B. Chicago Medicine 2001;104:28-31.

  • Fonatana RJ, Hann HWL, Perrillo R, Vierling J, Wright T, Rakela J, Anschuetz G, Davis R, Gardener S, Brown N. Determinants of survival in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719-727.

  • Hann HWL. Prevention of hepatocellular carcinoma: antiviral therapy, preneoplastic markers and iron nutrition. The Korean Journal of Gastroenterology 2002; 39: 105-109

  • Dienstag JL, Goldin R, Heathcote EJ, Hann HWL, Woessner M, Stephenson SL, Gardner S, Gray F, Schiff ER. Histological outcome during long-term lamivudine therapy: impact of YMDD-variant hepatitis B virus. Gastroenterology 2003; 124:105-117

  • Hann HWL. Fonatana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Gardner S, Brwon N, Griffiths for the U.S. lamivudine compassionate use study group. A US compassionate use study of lamivudine treatment in non-transplant candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transplantation 2003;9:49-56

  • Peters MG, Hann HW, Heathcote E, Martin P, Buggisch P, Rubin R, Bourliere M, Kowdley K, Metreau JM, Trepo C, Gray DF, Sullivan M, Kleber K, Ebrahim R, Xiong S, Brosgart C for the GS-00-461 Study Group. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine resistant hepatitis B virus: Results of 48 week, randomized, multicenter study. Gastroenterology 2004;126:91-101

  • Perrillo R, Hann HW L, Mutimer D, Willems B, Leung N, Lee W, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart C and Schiff E. Adefovir dipivoxil added to maintenance lamivudine in chronic hepatitis B with YMDD mutant HBV and a reduced response to lamivudine. Gastroenterology 2004;126:81-90

  • Hann HWL, Lee, JM, Bussard A, Liu C, Jin YR, Guha K, Clayton MM, Ardlie K, Pellini M, Feitelson MA. Early markers of hepatocellular carcinoma in hepatitis B virus carriers. Cancer Res 2004; 64:7329-7335.

  • Hann HWL, Funk MLJ, Rosenberg DM, Davis R. Factors associated with response to lamivudine: a retrospective study in a tertiary care clinic serving patients with chronic hepatitis B. J of Gastroenterology and Hepatology 2005; 20:433-440.

  • Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA. A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.Gastroenterology 2005;129:528-526.

  • Communale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, Evans AA, Hann HWL, Block TM, Mehta AS. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res 2006;5:308-315.

  • Hann HW. Traditional Chinese Medicine for hepatitis B. New Horizons 2006; 7 (1): 6-8.

  • Hann HWL, Hann RS, Maddrey WC. Hepatitis B virus infection in 6,130 unvaccinated Korean-Americans surveyed between 1988 and 1990. Am J Gastroenterol 2007; 102: 1-6.

  • Chae HB, Hann HW. Time for An Active Antiviral Therapy for Hepatitis B: An update on the management of hepatitis B virus infection. Therapeutics and Clinical Risk Management. 2007;3:605-612.

  • Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breatkthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13: 4085-90.

  • Choi D, Mitchell DG, Verma SK, Bergin D, Navarro VJ,Malliah AB, McGowan C, Hann HWL, Herrine SK. Hepatocellular carcinoma with indeterminate or false-negatice findings at initial MRI imaging. Effect on eligibility for curative treatment. Initial observations. Radiology 2007; 244:776-83.

  • Hann HWL. HBV Screening and counseling strategies for general practitioners. Johns

  • Hopkins Advanced studies in Medicine 2007; 7:476-481.

  • Hann HW, Han S.H, Block TM, Harris M, Maa JF, Fisher RT, Attilasoy E Symptomatology and health attitudes of Chronic hepatitis B patients in the United States. J of Med. Virol 2008; 15:42-51.

  • Hann HW. Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma.. Minerva Gastroenterologica e Dietologica 2008: 54:19-30.

  • Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM) resistant hepatitis B virus (HBV). Hepatol Int 2008;2:244-249.

  • Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one year incidence of resistance to lamivudine in the treatment of chronic hepaitis B. Hepatol Int 2008;2:440-456.

  • Lim SG, Leung N, Hann HWL, Laur GKK, Trepo C, Mommeija-Marin H, Mozham C, Sorbel J, Snow A, Blum MR, Rousseau F, Marcellin P. A phase I, randomized trial evaluating the safety, pharmacokinetics and antivral activity of Clevudine for 12 weeks in patients with chronic hepatitis B. Alim Pharm and Ther 2008;27:1282-1292.

  • Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J. Early hepatitis B virus DNA reduction of hepatitis Be Antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-79.

  • 9 Book Chapters

  • Hann, HWL., Levy, H.M. and Evans, A.E. Ferritin and cancer: Study of isoferritins in patients with neuroblastoma. In Advances in Neuro-blastoma Research. Ed. Evans, A.E., Raven Press, pp. 43-48, 1980.

  • Hann, HWL., Stahlhut, M.W. and Evans, A.E. Isoferritins and prognosis of neuroblastoma: The immunological role of acidic isoferritins. In Ferritins and Isoferritins as Biochemical Markers. Eds. A. Albertini, et al., Elsevier Science Publishers B.V., Amsterdam, pp 171-180, 1984.

  • Hann, HWL., Stahlhut, M.W. and Evans, A.E. Serum ferritin as a prognostic indicator in neuroblastoma: Biological effects of isoferritins. In: Third Conference on Advances in Neuroblastoma Research. Eds. A.E. Evans, G.J. D'Angio and R.C. Seeger, Alan R. Liss, New York, pp 331-345, 1985.

  • McGlynn, K., London, W.T., Hann, HWL. and Sharrar, R.G. Prevention of primary hepatocellular carcinoma in Asian populations in the Delaware Valley. Prog. Clin. Biol. Res., Vol. 216, In Advances in Cancer Control: Health Care Financing and Research. Eds. L.E. Mortenson, P.F. Engstrom and P.N. Anderson. Alan R. Liss, Inc., New York, pp. 237-246, 1986.

  • Hann, HWL., London, W.T., McGlynn, K. and Blumberg, B.S. Prevention of hepatitis B and primary liver cancer in Asian populations in the United States. Proceedings of THE NEXT DECADE, the 1986 Conference on Refugee Health Care Issues and management. Eds. T. Phan and M.. Katcher, Wisconsin Refugee Health Program, Wisconsin Division of Health, pp. 95-109, 1987.

  • Israel, J.L., McGlynn, K.A., Hann, HWL. and Blumberg, B.S. Iron-related markers in liver cancer. In Iron in Immunity, Cancer and Inflammation. Eds. M. DeSousa and J. Brock, John Wiley & Sons, Sussex, England. pp 301-316, 1989.

  • Finlay, J. and Hann, HWL. Tumor markers. In Pediatric Oncology Handbook. Eds. G.J. D'Angio and D. Sinniah. Edward Arnold, Publisher, London, Chap. 2 pp. 16-22, 1992

  • Hann, HWL. Hepatitis B. Chapter 5, In Confronting Critical Health Issues of Asian and Pacific Islander Americans Eds. Zane, Takeuchi and Young, Sage Publications, pp. 149-173, 1994.

  • Hann, HWL, Bombardieri, E. Serum markers and prognosis in neuroblastoma: ferritin, LDH and NSE. Chapter 29, In Neuroblastoma, Eds. Brodeur, Sawada, Tsuchida and Voute. Elsevier Sciences, B.V. pp.371-381, 2000

Individual Expertise profile of Hie-Won Yvonne Hann, Copyright © Hie-Won Yvonne Hann.
Last Updated by Hie-Won Hann : Thursday, May 14, 2009 3:51:08 PM



Maintained by Steven Herrine
Copyright © Thomas Jefferson University. All Rights Reserved.

 Printable Version

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement.
Thomas Jefferson University
Thomas Jefferson University